Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 13Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Neoplasms 4Lung Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Skin Diseases 2Pancreatic Neoplasms 2Hematologic Neoplasms 2Uveal Melanoma 1Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Soft Tissue Neoplasms 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Low-grade Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1

Interventions

binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Low-grade Serous Ovarian Cancer × binimetinib × Clear all
NCT01849874 2023-10-30

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Pfizer

Phase 3 Terminated
341 enrolled 15 charts
Gynecologic

Low-grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡